Ulf Schnetzke
YOU?
Author Swipe
View article: Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients Open
In the European LeukemiaNet (ELN) 2022 recommendations, myelodysplasia-related (MR) gene mutations were classified as a novel adverse prognostic category for intensively treated acute myeloid leukemia (AML). To assess the prognostic impact…
View article: Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced‐stage Hodgkin lymphoma in older patients
Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced‐stage Hodgkin lymphoma in older patients Open
View article: 159 | R‐POLA‐GLO – CHEMO‐LIGHT FRONTLINE THERAPY INDUCES HIGH RESPONSE RATES WITH A FAVORABLE SAFETY PROFILE IN ELDERLY/FRAIL PATIENTS WITH AGGRESSIVE LYMPHOMA
159 | R‐POLA‐GLO – CHEMO‐LIGHT FRONTLINE THERAPY INDUCES HIGH RESPONSE RATES WITH A FAVORABLE SAFETY PROFILE IN ELDERLY/FRAIL PATIENTS WITH AGGRESSIVE LYMPHOMA Open
View article: 327 | LONG‐TERM OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA ACHIEVING CR USING BISPECIFIC ANTIBODIES
327 | LONG‐TERM OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA ACHIEVING CR USING BISPECIFIC ANTIBODIES Open
View article: 232 | COMBINATION OF THE INTRAVENOUS PI3K INHIBITOR COPANLISIB IN COMBINATION WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA AND HIGH TUMOR BURDEN
232 | COMBINATION OF THE INTRAVENOUS PI3K INHIBITOR COPANLISIB IN COMBINATION WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA AND HIGH TUMOR BURDEN Open
View article: 828 | TRIAL IN PROGRESS: PEMBROLIZUMAB IN COMBINATION WITH SALVAGE CHEMOTHERAPY FOR FIRST‐RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (PEMBRO‐CORE)
828 | TRIAL IN PROGRESS: PEMBROLIZUMAB IN COMBINATION WITH SALVAGE CHEMOTHERAPY FOR FIRST‐RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (PEMBRO‐CORE) Open
View article: 716 | CD19‐DIRECTED CHIMERIC ANTIGEN RECEPTOR‐CELL THERAPY FOR B‐CELL LYMPHOMAS WITH PRIMARY OR SECONDARY CNS INVOLVEMENT. REAL‐WORLD DATA FROM A MULTICENTER ANALYSIS
716 | CD19‐DIRECTED CHIMERIC ANTIGEN RECEPTOR‐CELL THERAPY FOR B‐CELL LYMPHOMAS WITH PRIMARY OR SECONDARY CNS INVOLVEMENT. REAL‐WORLD DATA FROM A MULTICENTER ANALYSIS Open
View article: 358 | PD‐1‐BASED SALVAGE THERAPY FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A MULTICENTER REAL‐WORLD ANALYSIS
358 | PD‐1‐BASED SALVAGE THERAPY FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A MULTICENTER REAL‐WORLD ANALYSIS Open
View article: PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma
PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma Open
View article: Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma Open
Patients with large B-cell lymphoma (LBCL) who experience relapsed disease after CD19-directed chimeric antigen receptor (CAR) T-cell (CAR-T) therapy have a poor prognosis. Bispecific antibodies (BsAbs) induce complete remissions in ∼35% o…
View article: Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG–NLG phase II BVB trial
Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG–NLG phase II BVB trial Open
View article: Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study
Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study Open
Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after at least 2 prior treatment lines, but real-world data are scarce. In this retrospective, multicen…
View article: Correction to: Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Correction to: Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia Open
View article: Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma Open
Introduction Patients (pts) with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after CD19 chimeric antigen receptor (CAR)-T cell therapy are challenging to treat. CD20xCD3 T-cell-engaging bispecific antibodies (BsAbs) have emer…
View article: Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia Open
The combination of venetoclax with hypomethylating agents is currently the standard of care for elderly patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. Despite its favorable efficacy, clinical use is often…
View article: Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome
Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome Open
Lambert-Eaton myasthenic syndrome (LEMS) is an autoantibody-mediated disease of the neuromuscular junction characterized by muscular weakness. Autoantibodies to presynaptic P/Q-type voltage-gated calcium channels (VGCCs) induce defective n…
View article: Validating genetic variants in innate immunity linked to infectious events in acute myeloid leukemia post-induction chemotherapy
Validating genetic variants in innate immunity linked to infectious events in acute myeloid leukemia post-induction chemotherapy Open
Infectious events, such as sepsis and invasive fungal disease (IFD), pose significant risks in patients with acute myeloid leukemia (AML). Previous studies, including our own, have suggested a potential role of single nucleotide polymorphi…
View article: Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study
Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study Open
View article: Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation
Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation Open
Inhibition of menin in acute myeloid leukemia (AML) harboring histone-lysine-N-methyltransferase 2A rearrangement (KMT2Ar) or the mutated Nucleophosmin gene (NPM1c) is considered a novel and effective treatment approach in these patients. …
View article: Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis Open
Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome driven by pathologic activation of cytotoxic T-lymphocytes and macrophages. Despite advances in diagnostics and management, adult patients with lymphoma-associ…
View article: Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed / refractory large B-cell lymphoma: findings from a German monocentric study.
Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed / refractory large B-cell lymphoma: findings from a German monocentric study. Open
Incorporating chimeric antigen receptor (CAR)-T cell therapy into relapsed or refractory large B-cell lymphoma (rr LBCL) treatment algorithms has yielded remarkable response rates and durable remissions, yet a substantial portion of patien…
View article: Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis
Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis Open
The outcome of patients with large B cell lymphoma (LBCL) who relapse or progress after CD19-directed chimeric antigen receptor T cell therapy (CAR-T) administered as salvage therapy beyond the second treatment line is poor. However, a min…
View article: P07.15.B NEUROMUSCULAR HIGH-RESOLUTION ULTRASOUND IN PERIPHERAL NEUROTOXICITY OF SYSTEMICALLY TREATED CANCER PATIENTS
P07.15.B NEUROMUSCULAR HIGH-RESOLUTION ULTRASOUND IN PERIPHERAL NEUROTOXICITY OF SYSTEMICALLY TREATED CANCER PATIENTS Open
BACKGROUND Up to 40 % of cancer patients treated with neurotoxic cytostatic chemotherapies develop treatment-induced peripheral neuropathy. Furthermore, in patients treated with immune checkpoint inhibitors neuromuscular immune-related adv…
View article: PB1774: PHARMACOLOGICAL STRATEGIES TO OVERCOME RESISTANCE IN AML CELL LINE MODELS HARBORING ACTIVATING FLT3-ITD AND PTPN11 MUTATIONS
PB1774: PHARMACOLOGICAL STRATEGIES TO OVERCOME RESISTANCE IN AML CELL LINE MODELS HARBORING ACTIVATING FLT3-ITD AND PTPN11 MUTATIONS Open
Topic: 3. Acute myeloid leukemia - Biology & Translational Research Background: Primary or secondary resistance towards various AML-treatment strategies like intensive chemotherapy, tyrosine kinase inhibitors or combination of the BCL-2 in…
View article: Staphylococcus intermedius infection with splenic abscesses in a patient with acute lymphoblastic leukemia
Staphylococcus intermedius infection with splenic abscesses in a patient with acute lymphoblastic leukemia Open
View article: Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience
Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience Open
View article: P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY
P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY Open
Background: Information on the long-term outcome of patients who relapse or progress after CD19-directed CAR-T therapy with axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) for >2L treatment of LBCL is still limited. Aims: …
View article: Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia
Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia Open
Background Infectious complications reflect a major challenge in the treatment of patients with acute myeloid leukemia (AML). Both induction chemotherapy and epigenetic treatment with hypomethylating agents (HMA) are associated with severe…
View article: Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma
Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma Open
Conditioning with treosulfan and fludarabine (Treo/Flu) has been proven to be feasible and efficient in several types of malignancies before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Given its favorable reduced toxici…
View article: GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany
GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany Open
CD19-directed chimeric antigen receptor (CAR) T cells have evolved as new standard-of-care (SOC) treatment in patients with relapsed/refractory large B-cell lymphoma (LBCL). Here, we report the first German real-world data on SOC CAR-T cel…